[go: up one dir, main page]

MX2018010788A - Composicion oftalmologica. - Google Patents

Composicion oftalmologica.

Info

Publication number
MX2018010788A
MX2018010788A MX2018010788A MX2018010788A MX2018010788A MX 2018010788 A MX2018010788 A MX 2018010788A MX 2018010788 A MX2018010788 A MX 2018010788A MX 2018010788 A MX2018010788 A MX 2018010788A MX 2018010788 A MX2018010788 A MX 2018010788A
Authority
MX
Mexico
Prior art keywords
composition
hyaluronic acid
ophthalmological composition
ectoine
derivative
Prior art date
Application number
MX2018010788A
Other languages
English (en)
Other versions
MX382534B (es
Inventor
Holzer Frank
Steinfeld Ute
Mahler Markus
Warda Isabella
Original Assignee
Ursapharm Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58264510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018010788(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ursapharm Arzneimittel Gmbh filed Critical Ursapharm Arzneimittel Gmbh
Publication of MX2018010788A publication Critical patent/MX2018010788A/es
Publication of MX382534B publication Critical patent/MX382534B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición oftalmológica con alta viscosidad. La composición de acuerdo con la invención contiene o consta de ácido hialurónico o de un derivado de ácido hialurónico como, por ejemplo, una sal oftalmológicamente aceptable de ácido hialurónico así como ectoína o un derivado de ectoína oftalmológicamente aceptable. La composición está caracterizada además porque no comprende ningún otro ingrediente farmacéuticamente activo.
MX2018010788A 2016-03-07 2017-03-07 Composicion oftalmologica MX382534B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102016203696.3A DE102016203696A1 (de) 2016-03-07 2016-03-07 Ophthalmologische Zusammensetzung
PCT/EP2017/055338 WO2017153415A1 (de) 2016-03-07 2017-03-07 Ophthalmologische zusammensetzung

Publications (2)

Publication Number Publication Date
MX2018010788A true MX2018010788A (es) 2019-01-14
MX382534B MX382534B (es) 2025-03-13

Family

ID=58264510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010788A MX382534B (es) 2016-03-07 2017-03-07 Composicion oftalmologica

Country Status (14)

Country Link
US (1) US20190099441A1 (es)
EP (1) EP3426226B1 (es)
JP (1) JP2019511494A (es)
KR (1) KR20180117635A (es)
CN (1) CN108778250A (es)
AU (1) AU2017231697B2 (es)
BR (1) BR112018067995B1 (es)
DE (1) DE102016203696A1 (es)
ES (1) ES2922821T3 (es)
LT (1) LT3426226T (es)
MX (1) MX382534B (es)
PT (1) PT3426226T (es)
RU (1) RU2749723C2 (es)
WO (1) WO2017153415A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016203696A1 (de) 2016-03-07 2017-09-07 Ursapharm Arzneimittel Gmbh Ophthalmologische Zusammensetzung
CN109771427A (zh) * 2019-01-30 2019-05-21 上海克琴科技有限公司 一种通过提高依克多因光学纯度来增强其安全性和抗炎抗过敏活性的方法
EP3827818A1 (en) * 2019-11-26 2021-06-02 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic composition
CN110974830A (zh) * 2019-12-26 2020-04-10 华熙生物科技股份有限公司 一种用于预防、缓解或治疗皮肤过敏的外用组合物及其用途
CN111518627A (zh) * 2020-05-09 2020-08-11 华熙生物科技股份有限公司 一种隐形眼镜护理液以及制备方法
DE102020112603A1 (de) * 2020-05-10 2021-11-11 Bitop Aktiengesellschaft Kompatible Solute zur Prävention oder Behandlung von SARS-CoV-2-Infektionen
CN111467349B (zh) * 2020-05-14 2021-06-01 华熙生物科技股份有限公司 人工泪液及其制备方法
CN111407774B (zh) * 2020-05-15 2022-03-22 华熙生物科技股份有限公司 一种眼科用组合物及其制备方法
CN111905094B (zh) * 2020-06-15 2022-08-09 华熙生物科技股份有限公司 一种眼用组合物及其在制备用于干眼症的药物中的用途
CN112220102B (zh) * 2020-09-25 2022-12-09 山东华熙海御生物医药有限公司 一种含透明质酸和依克多因的电子烟液及其制备方法
CN112480483B (zh) * 2020-11-27 2022-02-01 华熙生物科技股份有限公司 一种依克多因-透明质酸复合凝胶的制备方法及所得产品
CN112870455B (zh) * 2021-02-05 2022-05-24 华熙生物科技股份有限公司 一种含透明质酸的凝胶制剂、制法及其在内窥镜检查中的应用
US12012238B2 (en) * 2021-05-26 2024-06-18 Bausch + Lomb Ireland Limited Packaging solutions
CN116139067B (zh) * 2021-11-22 2024-03-22 华熙生物科技股份有限公司 透明质酸锌形成凝胶的方法及含有透明质酸锌的滴眼凝胶及其制备
CN114569491B (zh) * 2022-04-18 2023-08-18 华熙生物科技股份有限公司 一种抑制油脂生成的组合物及其用途
CN115317598A (zh) * 2022-09-22 2022-11-11 深圳中科欣扬生物科技有限公司 一种用于口腔溃疡的含sod贴剂及其制备方法
CN116024050A (zh) * 2022-12-14 2023-04-28 江苏视准医疗器械有限公司 一种角膜接触镜保存液组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4342560A1 (de) 1993-12-14 1995-06-22 Marbert Gmbh Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten
JP4540872B2 (ja) * 2001-04-02 2010-09-08 株式会社資生堂 乾燥による皮膚傷害の抑制剤もしくは修復剤
DE10161110A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
US7160560B2 (en) * 2003-10-23 2007-01-09 L'oreal S.A. Skin-care composition
DE102007052380A1 (de) 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
CN101491526A (zh) * 2009-03-03 2009-07-29 山东大学 四氢嘧啶在制备治疗关节炎的药物中的应用
DE102014007423A1 (de) * 2014-05-22 2015-11-26 Bitop Ag Zusammensetzung zur Behandlung des Auges
DE102016203696A1 (de) 2016-03-07 2017-09-07 Ursapharm Arzneimittel Gmbh Ophthalmologische Zusammensetzung

Also Published As

Publication number Publication date
US20190099441A1 (en) 2019-04-04
RU2749723C2 (ru) 2021-06-16
DE102016203696A1 (de) 2017-09-07
CA3015592A1 (en) 2017-09-14
KR20180117635A (ko) 2018-10-29
PT3426226T (pt) 2022-07-20
AU2017231697A1 (en) 2018-09-13
ES2922821T3 (es) 2022-09-20
LT3426226T (lt) 2022-07-25
RU2018130713A (ru) 2020-04-08
JP2019511494A (ja) 2019-04-25
MX382534B (es) 2025-03-13
EP3426226A1 (de) 2019-01-16
BR112018067995B1 (pt) 2023-09-26
BR112018067995A2 (pt) 2019-01-15
RU2018130713A3 (es) 2020-06-30
WO2017153415A1 (de) 2017-09-14
AU2017231697B2 (en) 2022-07-07
EP3426226B1 (de) 2022-05-04
CN108778250A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
MX382534B (es) Composicion oftalmologica
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MY210123A (en) Tlr7/8 antagonists and uses thereof
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EP4309735A3 (en) Pharmaceutical composition of s-ketamine hydrochloride
MY180526A (en) Pharmaceutical composition of s-ketamine hydrochloride
MY185491A (en) Macrocylic pyrimidine derivatives
MY185500A (en) Macrocylic pyridine derivatives
NZ717825A (en) Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
WO2015152577A3 (ko) 골 질환 예방 및 치료용 조성물
MD20160040A2 (ro) Pidotimod pentru utilizare în tratamentul bolilor asociate cu inflamaţie
PH12018500579A1 (en) Fungal keratitis prophylactic or therapeutic agent
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
WO2016027160A3 (en) Nasal composition comprising mixture of hyaluronic acids and saline solution
MX2021000040A (es) Formulaciones farmaceuticas estables de oximetazolina.
PH12016502527B1 (en) Stabilized desmopressin
WO2019125166A3 (en) Hyaluronic acid formulations